Lotti Francesco, Menguzzato Emilio, Rossi Claudia, Naldini Luigi, Ailles Laurie, Mavilio Fulvio, Ferrari Giuliana
TIGET, Istituto Scientifico H. San Raffaele, 20132 Milan, Italy.
J Virol. 2002 Apr;76(8):3996-4007. doi: 10.1128/jvi.76.8.3996-4007.2002.
Gene therapy of many genetic diseases requires permanent gene transfer into self-renewing stem cells and restriction of transgene expression to specific progenies. Human immunodeficiency virus (HIV)-derived lentiviral vectors are very effective in transducing rare, nondividing stem cell populations (e.g., hematopoietic stem cells) without altering their long-term repopulation and differentiation capacities. We developed a strategy for transcriptional targeting of lentiviral vectors based on replacing the viral long terminal repeat (LTR) enhancer with cell lineage-specific, genomic control elements. An upstream enhancer (HS2) of the erythroid-specific GATA-1 gene was used to replace most of the U3 region of the LTR, immediately upstream of the HIV type 1 (HIV-1) promoter. The modified LTR was used to drive the expression of a reporter gene (the green fluorescent protein [GFP] gene), while a second gene (a truncated form of the p75 nerve growth factor receptor [DeltaLNGFR]) was placed under the control of an internal constitutive promoter to monitor cell transduction, or to immunoselect transduced cells, independently from the expression of the targeted promoter. The transcriptionally targeted vectors were used to transduce cell lines, human CD34+ hematopoietic stem-progenitor cells, and murine bone marrow (BM)-repopulating stem cells. Gene expression was analyzed in the stem cell progeny in vitro and in vivo after xenotransplantation into nonobese diabetic-SCID mice or BM transplantation in coisogenic mice. The modified LTR directed high levels of transgene expression specifically in mature erythroblasts, in a TAT-independent fashion and with no alteration in titer, infectivity, and genomic stability of the lentiviral vector. Expression from the modified LTR was higher, better restricted, and showed less position-effect variegation than that obtained by the same combination of enhancer-promoter elements placed in a conventional, internal position. Cloning of the woodchuck hepatitis virus posttranscriptional regulatory element at a defined position in the targeted vector allowed selective accumulation of the genomic transcripts with respect to the internal RNA transcript, with no loss of cell-type restriction. A critical advantage of this targeting strategy is the use of a spliced, major viral transcript to express a therapeutic gene and that of an internal, independently regulated promoter to express an additional gene for either cell marking or in vivo selection purposes.
许多遗传疾病的基因治疗需要将基因永久转移到自我更新的干细胞中,并将转基因表达限制在特定的子代细胞中。源自人类免疫缺陷病毒(HIV)的慢病毒载体在转导罕见的、非分裂的干细胞群体(如造血干细胞)方面非常有效,且不会改变它们的长期再增殖和分化能力。我们开发了一种基于用细胞谱系特异性的基因组控制元件取代病毒长末端重复序列(LTR)增强子的慢病毒载体转录靶向策略。红系特异性GATA-1基因的上游增强子(HS2)被用于取代LTR的大部分U3区域,该区域位于1型人类免疫缺陷病毒(HIV-1)启动子的紧上游。修饰后的LTR被用于驱动报告基因(绿色荧光蛋白[GFP]基因)的表达,而第二个基因(截短形式的p75神经生长因子受体[DeltaLNGFR])则置于内部组成型启动子的控制之下,以监测细胞转导,或独立于靶向启动子的表达对转导细胞进行免疫筛选。转录靶向载体被用于转导细胞系、人CD34+造血干祖细胞以及小鼠骨髓(BM)再增殖干细胞。在将其异种移植到非肥胖糖尿病-严重联合免疫缺陷小鼠体内或同基因小鼠中进行BM移植后,在体外和体内对干细胞子代中的基因表达进行了分析。修饰后的LTR以不依赖于反式激活转录激活因子(TAT)的方式,特异性地在成熟成红细胞中指导高水平的转基因表达,且慢病毒载体的滴度、感染性和基因组稳定性没有改变。与置于传统内部位置的相同增强子-启动子元件组合相比,修饰后的LTR的表达更高、限制更好且位置效应斑驳更少。在靶向载体的特定位置克隆土拨鼠肝炎病毒转录后调控元件,可使基因组转录本相对于内部RNA转录本选择性积累,同时不丧失细胞类型限制。这种靶向策略的一个关键优势是使用剪接的主要病毒转录本表达治疗基因,以及使用内部独立调控的启动子表达另一个用于细胞标记或体内选择目的的基因。